Green Cross Holdings invested in an American bio venture to develop gene therapy
Gr
een Cross Holdings (President Byung-geon Lee) announced on the 14th that it has participated in the Series B-2 Round of the American bio venture ‘Juventas Therapeutics(hereinafter referring to Juventas)’ as quota investment worth of $7.5 million along with an affiliated investment company, Posc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
